Levoketoconazole
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2021
- First approval year
- 2021
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Levoketoconazole
- Molecular weight
- 531.44
- Structure (SMILES)
- CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
- recorlev
- Recorlev
- (-)-(2s,4r)-ketoconazole
- 2s 4r ketoconazole
- 2s,4r ketoconazole
- 2s,4r-ketoconazole
- cor 003
- COR-003
- cor003
- COR003
- dio 902
- DIO-902
- ketoconazole 2s 4r
- Ketoconazole, (2s,4r)-
- levoketoconazol
- Levoketoconazol
- levoketoconazole
- Levoketoconazole
- Levoketoconazole [INN]
- Levoketoconazole [USAN]
- Levoketoconazole [WHO-DD]
- levoketoconazole inn
- levoketoconazole usan
- levoketoconazole who dd
- normocort
- Normocort
- ATC classification codes
- H02CA04
Sources for recorded values
- CAS registry numbers
- 142128-57-2
- ChEMBL ID
- CHEMBL295698
- InChIKey
- XMAYWYJOQHXEEK-ZEQKJWHPSA-N
- PubChem compound IDs
- 47576
- RxNorm IDs (RxCUI)
- 2588846
- FDA ingredient codes (UNII)
- 2DJ8R0NT7K
- Applicant
- STRONGBRIDGE
- Approval date
- 30 Dec 2021
- Application number
- NDA214133
- Patents
- 9
- Designations
- 1
- Earliest recorded loss of exclusivity
- 2 Mar 2040
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- levoketoconazole
- Type
- Synthetic organic
- Drug name stem
- -conazole
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- CYP17A1
- Gene symbol
- CYP17A1
- Protein identifier
- P05093
- Median affinity
- 7.42
- Affinity units
- pKi
- Mechanism
- Cytochrome P450 11A1 inhibitor
- Action type
- Inhibitor
- Target
- Cholesterol side-chain cleavage enzyme, mitochondrial
- Protein identifier
- P05108
- Mechanism
- Cytochrome P450 11B1 inhibitor
- Action type
- Inhibitor
- Target
- Cytochrome P450 11B1, mitochondrial
- Protein identifier
- P15538
- Mechanism
- Cytochrome P450 11B2 inhibitor
- Action type
- Inhibitor
- Target
- Cytochrome P450 11B2, mitochondrial
- Protein identifier
- P19099
- Mechanism
- Cytochrome P450 17A1 inhibitor
- Action type
- Inhibitor
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Protein identifier
- P05093
- Mechanism
- Cytochrome P450 11A1 inhibitor
- Action type
- Inhibitor
- Target
- Cholesterol side-chain cleavage enzyme, mitochondrial
- Mechanism
- Cytochrome P450 11B1 inhibitor
- Action type
- Inhibitor
- Target
- Cytochrome P450 11B1, mitochondrial
- Mechanism
- Cytochrome P450 11B2 inhibitor
- Action type
- Inhibitor
- Target
- Cytochrome P450 11B2, mitochondrial
- Mechanism
- Cytochrome P450 17A1 inhibitor
- Action type
- Inhibitor
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Condition
- Cushing Syndrome
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003099
- Subject identifier
- D003480
- Condition
- Adrenal Gland Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005539
- Subject identifier
- D000307
- Condition
- Adrenocortical Hyperfunction
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000797
- Subject identifier
- D000308
- Condition
- Pituitary ACTH Hypersecretion
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001110
- Subject identifier
- D047748
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0003099
- Condition identifier
- EFO_0005539
- Condition identifier
- EFO_1000797
- Condition identifier
- EFO_1001110
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005495
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006640
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0018912
- Highest recorded phase
- 4
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Country
- United States
- NCT00494663
- NCT00622089
- NCT01838551
- NCT03277690
- NCT03621280
- Dose
- 150 mg
- Route
- Oral
- How often
- Twice daily, then titrate by 150 mg daily no more frequently than every 2-3 weeks, maximum 1200 mg daily as 600 mg twice daily, may reduce to once daily
Conditions of use
- Take with or without food
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 0
- Polar surface area
- 69.06
- Calculated partition coefficient (ALogP)
- 4.21
- Calculated partition coefficient (XLogP)
- 4.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 36
- Molecular formula
- C26H28Cl2N4O4
- Monoisotopic mass
- 530.1487608
- Natural product
- Yes
- 72065-003
- Recorded assays
- 302
- Active assays
- 17
- Confirmatory
- Other
- Antifungal Agents
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
These details could not be displayed.
Related records
Trials (26)
- A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus
- A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes
- A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
- A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
- Alternation in the Human Microbiome With Commonly Used Topical Medications
- An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot
- Bioavailability of Levoketoconazole and Ketoconazole Tablets
- Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
- Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
- Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
- Hormonal Mechanisms of Sleep Restriction - Axis Study
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
- ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
- Ketoconazole Foam 2% for the Treatment of Versicolor
- Levoketoconazole Food Effect Study in Healthy Subjects
- Mycological Efficacy and Safety of Ketoconazole 2% Shampoo With a Seven-Day Versus Three-Day Treatment Duration in Pityriasis Versicolor
- Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
- Open-label Treatment in Cushing's Syndrome
- Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole
- Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis
Approved for (3)
- Adrenal gland disorder
- Adrenal gland hyperfunction
- Cushing syndrome
In development for (2)
- ACTH-dependent Cushing syndrome Phase 3
- Type 2 diabetes mellitus Phase 2